Answers are grounded in this paper and cite their sources.
We report the case of a 63‐year‐old woman with an exuberant and recalcitrant clinical presentation of LP who had an excellent response to 200 mg/day abrocitinib, a JAK‐1 inhibitor, after failure to other commonly used therapies. The efficacy of JAK inhibitors in lichen planus is supported by small case series and isolated case reports. Further studies are necessary to confirm their full potential.
No takes yet. Share an insight, caveat, or question.
Siems et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: